What does CIAS stand for?

Cognitive Impairment Associated with Schizophrenia

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Canadian International Auto Show Center for Information Assurance and Security (University of Texas, Austin) Center for Infrastructure Assurance and Security (University of Texas, San Antonio) Center for Integrated Agricultural Systems (UW-Madison) Center for International and Area Studies Center for Investment Advisory Services Centre Intercommunal d'Action Sociale (French: Intermunicipal Center for Social Action) Certified Investment Agent Specialist (real estate industry) Changi International Airport Services (Singapore) Circuit Inventory & Analysis System		College of Imaging Arts and Science (Rochester Institute of Technology) Computer Imaging Analysis Software Conseil International de l'Action Sociale counterintelligence analysis section (US DoD) Cold-Induced Autoinflammatory Syndrome 1 Cayman Islands Amateur Swimming Association Center for Impact Assessment Studies and Forecasting (Poland) Asian Exposition on Chemicals and Instrumentation Committee on International Aviation Safety and Security Central Information Agency for Science and Technology

Samples in periodicals archive:

Psychiatric diseases focused on in this report: schizophrenia; depression; anxiety; addiction; attention-deficit/hyperactivity disorder (ADHD); cognitive impairment associated with schizophrenia (CIAS).

Research and Markets: the Psychiatric Disease Pipeline: Fully ...

NASDAQ: EPIX) today announced statistically significant results from its Phase 1b clinical trial of PRX-07034 in obesity, the company's internally-discovered, novel 5-HT6 antagonist being developed for obesity, Alzheimer's disease and cognitive impairment associated with schizophrenia.

EPIX Pharmaceuticals Reports Preliminary Findings from Phase 1b ...

The company's focus is on AD, mild cognitive impairment (MCI), cognitive impairment associated with schizophrenia, and attention deficit hyperactivity disorder (ADHD).

Genetic Engineering News Reports on Neurobiotechnology Developments

This financing will allow us to complete a Phase II clinical trial with SGS742 in mild to moderate Alzheimer's disease and initiate clinical evaluation of SGS518 in cognitive impairment associated with schizophrenia (CIAS).

Saegis Pharmaceuticals, Inc. Completes $30 Million Private Financing; ...

Through licensing activity, development partnerships and internal discovery programs, Saegis Pharmaceuticals is building a portfolio of compounds with activity against a range of disorders of the brain and central nervous system, including Alzheimer's disease, mild cognitive impairment, and cognitive impairment associated with schizophrenia.

Saegis Pharmaceuticals Names Thorsten Melcher Vice President, ...